Fig. 2From: Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patientsKaplan-Meier curve for progression free survival (PFS) according to the presence of circulating tumour DNA (ctDNA) in plasma. In patients with detectable ctDNA, a median PFS of 33.29 weeks was observedBack to article page